



**PB 11 of 2025**

# **National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025**

---

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 January 2025

Rebecca Richardson  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care

---



---

## Contents

1 Name .....	1
2 Commencement.....	1
3 Authority .....	1
4 Schedules.....	1
<b>Schedule 1—Amendments commencing 1 February 2025</b>	<b>2</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
<b>Schedule 2—Amendments commencing 1 April 2025</b>	<b>7</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	7
<b>Schedule 3—Amendments commencing immediately after the     commencement of Schedule 2 to the <i>National Health     (Minimum Stockholding) Amendment Determination (No. 10)     2024 – 1 April 2025</i></b>	<b>8</b>
<i>National Health (Minimum Stockholding) Determination 2023</i>	8



---

## 1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025*.
- (2) This instrument may also be cited as PB 11 of 2025.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 February 2025.	1 February 2025
2. Schedule 1	1 February 2025.	1 February 2025
3. Schedule 2	1 April 2025.	1 April 2025
4. Schedule 3	Immediately after the commencement of Schedule 2 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024</i> .	1 April 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments commencing 1 February 2025

### *National Health (Minimum Stockholding) Determination 2023*

#### 1 Schedule 1 (table)

Omit:

Carmellose	Eye drops containing carmellose sodium 10 mg per mL, 15 mL	Application to the Eye	Refresh Liquigel	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand
Carmellose	Eye drops containing carmellose sodium 5 mg per mL, 15 mL	Application to the Eye	Refresh Tears Plus	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand
Carmellose with glycerin	Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL	Application to the Eye	Optive	between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand

#### 2 Schedule 1 (table)

After:

Glucose and ketone indicator-urine	Test strips, 50 (Keto-Diastix)	For External Use	Keto-Diastix	4 months stock by reference to usual PBS demand
------------------------------------	--------------------------------	------------------	--------------	---

insert:

Glyceryl trinitrate	Transdermal patch 36 mg	Transdermal	Minitran 10	between 1 February 2025 and 30 September 2025—0 months stock by reference to usual demand
Glyceryl trinitrate	Transdermal patch 54 mg	Transdermal	Minitran 15	between 1 February 2025 and 31 December 2025—0 months stock by reference to usual demand

#### 3 Schedule 1 (table)

Omit:

Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	APO-Levetiracetam	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	Keppra	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	Kerron	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	Levetiracetam GH	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Oral solution 100 mg per mL, 300 mL	Oral	Levetiracetam-AFT	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	APO-Levetiracetam	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Keppra	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Kevtam 1000	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levactam	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levetiracetam GH	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levetiracetam Mylan	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levetiracetam SZ	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levetiracetam Viatrix	between 1 August 2024 and 31 January 2025—4 months

				stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	Levi 1000	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.
Levetiracetam	Tablet 1 g	Oral	NOUMED LEVETIRACETAM	between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.

#### 4 Schedule 1 (table)

Omit:

Mirtazapine	Tablet 45 mg	Oral	NOUMED MIRTAZAPINE	between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand
-------------	--------------	------	-----------------------	---

#### 5 Schedule 1 (table)

After:

Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	4 months stock by reference to usual PBS demand
	insert:			
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	Ondansetron ODT Viartis	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viartis and Ondansetron Mylan ODT added together
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viartis	after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viartis and Ondansetron Mylan Tablets added together
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron Tablets Viartis	after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viartis and Ondansetron Mylan Tablets added together



---

## 6 Schedule 1 (table)

	After:				
Pioglitazone	Tablet 45 mg (as hydrochloride)	Oral	ARX-PIOGLITAZONE	4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together	
	insert:				
Piroxicam	Dispersible tablet 20 mg	Oral	Feldene-D	between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand	
Polyethylene glycol 400 with propylene glycol	Eye drops 4 mg-3 mg per mL, 15 mL	Application to the Eye	Optix	between 1 February 2025 and 30 April 2025—0 months stock by reference to usual demand	

## 7 Schedule 1 (table)

	Omit:			
Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	Oral	Triasyn 2.5/2.5	4 months stock by reference to usual PBS demand
	substitute:			
Ramipril with felodipine	Tablet 2.5 mg-2.5 mg (modified release)	Oral	Triasyn 2.5/2.5	between 1 February 2025 and 30 September 2025—0 months stock by reference to usual PBS demand

## 8 Schedule 1 (table)

	Omit:			
Telmisartan	Tablet 40 mg	Oral	NOUMED TELMISARTAN	between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand

## 9 Schedule 1 (table)

	After:			
Trandolapril	Capsule 500 micrograms	Oral	Dolapril 0.5	2.5 months stock by reference to usual demand
	insert:			
Trastuzumab	Powder for I.V. infusion 150 mg	Injection	Kanjinti	between 1 February 2025 and 31 March 2025—0 months

---

stock by reference to  
usual demand

**10 Schedule 1 (table)**

	Omit:			
Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	6 months stock by reference to usual PBS demand
	substitute:			
Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	(a) between 1 February 2025 and 31 March 2025—89,358 packs of a pack quantity of 1 (b) between 1 April 2025 and 30 September 2025—91,362 packs of a pack quantity of 1 (c) after 30 September 2025—6 months stock by reference to usual PBS demand

---

## Schedule 2—Amendments commencing 1 April 2025

### *National Health (Minimum Stockholding) Determination 2023*

#### 1 Schedule 1 (table)

Omit:				
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	4 months stock by reference to usual PBS demand
substitute:				
Clarithromycin	Powder for oral liquid 250 mg per 5 mL, 50 mL	Oral	Klacid	(a) between 1 April 2025 and 30 September 2025—17,180 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand

#### 2 Schedule 1 (table)

Omit:				
Diazepam	Oral liquid 10 mg per 10 mL, 100 mL	Oral	Diazepam Elixir	4 months stock by reference to usual PBS demand
substitute:				
Diazepam	Oral liquid 10 mg per 10 mL, 100 mL	Oral	Diazepam Elixir	(a) between 1 April 2025 and 30 September 2025—1,228 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand

#### 3 Schedule 1 (table)

After:				
Oxazepam	Tablet 30 mg	Oral	Murelax	5 months stock by reference to usual demand
insert:				
Oxybutynin	Transdermal patches 36 mg, 8	Transdermal	Oxytrol	6 months stock by reference to usual PBS demand

---

**Schedule 3—Amendments commencing immediately after  
the commencement of Schedule 2 to the *National  
Health (Minimum Stockholding) Amendment  
Determination (No. 10) 2024 – 1 April 2025***

***National Health (Minimum Stockholding) Determination 2023***

**1 Schedule 1 (table)**

Omit:

Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	Sublingual	Nitrolingual Pumpspray	6 months stock by reference to usual PBS demand
---------------------	--	------------	---------------------------	---

substitute:

Glyceryl trinitrate	Sublingual spray (pump pack) 400 micrograms per dose, 200 doses	Sublingual	Nitrolingual Pumpspray	(a) between 1 April 2025 and 30 September 2025—162,432 packs of a pack quantity of 1  (b) after 30 September 2025—6 months stock by reference to usual PBS demand
---------------------	--	------------	---------------------------	---